Marshall Wace LLP Sells 103,667 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD)

Marshall Wace LLP cut its stake in shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) by 31.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 230,441 shares of the company’s stock after selling 103,667 shares during the quarter. Marshall Wace LLP owned approximately 0.39% of Clearside Biomedical worth $1,122,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in CLSD. Vanguard Group Inc. raised its holdings in shares of Clearside Biomedical by 21.9% in the second quarter. Vanguard Group Inc. now owns 2,106,090 shares of the company’s stock valued at $10,256,000 after buying an additional 378,559 shares during the last quarter. Morgan Stanley raised its holdings in shares of Clearside Biomedical by 8,275.7% in the first quarter. Morgan Stanley now owns 358,647 shares of the company’s stock valued at $886,000 after buying an additional 354,365 shares during the last quarter. EAM Investors LLC bought a new position in shares of Clearside Biomedical in the second quarter valued at about $1,206,000. State Street Corp raised its holdings in shares of Clearside Biomedical by 316.7% in the second quarter. State Street Corp now owns 165,588 shares of the company’s stock valued at $806,000 after buying an additional 125,848 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Clearside Biomedical by 173.9% in the first quarter. Millennium Management LLC now owns 186,381 shares of the company’s stock valued at $460,000 after buying an additional 118,327 shares during the last quarter. 33.13% of the stock is owned by institutional investors and hedge funds.

Shares of CLSD stock opened at $4.04 on Thursday. The stock has a 50-day moving average price of $5.44 and a 200 day moving average price of $4.99. The firm has a market cap of $241.05 million, a price-to-earnings ratio of -8.78 and a beta of 1.73. Clearside Biomedical, Inc. has a 12 month low of $1.66 and a 12 month high of $7.73.

Clearside Biomedical (NASDAQ:CLSD) last posted its earnings results on Wednesday, November 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. Clearside Biomedical had a negative return on equity of 161.73% and a negative net margin of 652.60%. During the same quarter last year, the company posted ($0.05) earnings per share. On average, analysts expect that Clearside Biomedical, Inc. will post -0.21 EPS for the current year.

In other news, major shareholder Bradford T. Whitmore sold 99,400 shares of the business’s stock in a transaction dated Monday, August 30th. The stock was sold at an average price of $7.06, for a total transaction of $701,764.00. Following the completion of the transaction, the insider now directly owns 3,529,845 shares in the company, valued at approximately $24,920,705.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 321,488 shares of company stock valued at $2,227,836 over the last 90 days. Corporate insiders own 11.30% of the company’s stock.

CLSD has been the subject of a number of research analyst reports. JMP Securities reaffirmed a “buy” rating and issued a $11.00 price target on shares of Clearside Biomedical in a report on Tuesday. Zacks Investment Research upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Monday, November 15th. Wedbush reiterated a “buy” rating and issued a $18.00 price objective on shares of Clearside Biomedical in a research report on Tuesday, September 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Clearside Biomedical in a research report on Wednesday, September 22nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $11.95.

Clearside Biomedical Profile

Clearside Biomedical, Inc is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H.

Further Reading: How to interpret a stock’s beta number

Institutional Ownership by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.